Skip to content

Author

H. Kawakami

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Electronic patient-reported outcome monitoring and quality of life during later-line nivolumab therapy for advanced gastric cancer.

BACKGROUND Health-related quality of life (HRQoL) often deteriorates during later-line treatment for advanced gastric cancer. Although nivolumab monotherapy has been an established treatment option in this setting, HRQoL data remain limited. This study aimed to examine associations between symptomatic adverse events (A...

Y. Horie, S. Oyamada, H. Kawakami et al. · 0 citations
Review Open access Aug 2026

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.

BACKGROUND Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit compared with chemotherapy for patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC). We report OS and additional analyses at a minimum follow-up of 5 years....

K. Kato, J. Ajani, Y. Doki et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.